Recombinant Fusion Proteins
"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
| Descriptor ID |
D011993
|
| MeSH Number(s) |
D12.776.828.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".
This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in this website by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 3 | 6 | 9 |
| 1994 | 1 | 9 | 10 |
| 1995 | 3 | 13 | 16 |
| 1996 | 3 | 22 | 25 |
| 1997 | 4 | 16 | 20 |
| 1998 | 2 | 19 | 21 |
| 1999 | 3 | 17 | 20 |
| 2000 | 6 | 25 | 31 |
| 2001 | 2 | 18 | 20 |
| 2002 | 2 | 37 | 39 |
| 2003 | 9 | 24 | 33 |
| 2004 | 5 | 20 | 25 |
| 2005 | 4 | 23 | 27 |
| 2006 | 2 | 16 | 18 |
| 2007 | 3 | 15 | 18 |
| 2008 | 3 | 12 | 15 |
| 2009 | 5 | 8 | 13 |
| 2010 | 1 | 13 | 14 |
| 2011 | 5 | 10 | 15 |
| 2012 | 3 | 8 | 11 |
| 2013 | 4 | 5 | 9 |
| 2014 | 3 | 2 | 5 |
| 2015 | 1 | 7 | 8 |
| 2016 | 2 | 5 | 7 |
| 2017 | 3 | 3 | 6 |
| 2018 | 2 | 4 | 6 |
| 2019 | 2 | 2 | 4 |
| 2020 | 2 | 3 | 5 |
| 2021 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.
-
Review on the Safety and Efficacy of Brolucizumab for Neovascular Age-Related Macular Degeneration From Major Studies and Real-World Data. Asia Pac J Ophthalmol (Phila). 2023 Mar-Apr 01; 12(2):168-183.
-
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. J Clin Oncol. 2022 06 10; 40(17):1939-1948.
-
Suppression of Rheumatoid Arthritis by Enhanced Lymph Node Trafficking of Engineered Interleukin-10 in Murine Models. Arthritis Rheumatol. 2021 05; 73(5):769-778.
-
Therapy for lower-risk MDS. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):426-433.
-
Prolonged residence of an albumin-IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis. Nat Biomed Eng. 2021 05; 5(5):387-398.
-
The protein-protein interactions required for assembly of the Tn3 resolution synapse. Mol Microbiol. 2020 12; 114(6):952-965.
-
Abicipar pegol for neovascular age-related macular degeneration. Expert Opin Biol Ther. 2020 09; 20(9):999-1008.
-
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. 2020 06 15; 126(12):2821-2828.
-
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. Invest New Drugs. 2020 04; 38(2):457-467.
-
A chimeric, multivalent assembly of galectin-1 and galectin-3 with enhanced extracellular activity. Biomater Sci. 2019 Apr 23; 7(5):1852-1862.